About 30 results found for searched term "Raf" (0.036 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1669 | Regorafenib | VEGFR/PDGFR |
| BAY 73-4506 | ||
| Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. | ||
| M1761 | Vemurafenib (PLX4032) | Raf |
| RG7204; RO5185426 | ||
| Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. | ||
| M1827 | Sorafenib Tosylate | VEGFR/PDGFR |
| BAY 43-9006,Nexavar | ||
| Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. | ||
| M1855 | Dabrafenib Mesylate | Raf |
| GSK-2118436B | ||
| Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. | ||
| M1863 | RAF265 | Raf |
| CHIR-265 | ||
| RAF265 is a novel, orally bioavailable dual inhibitor of RAF kinase and VEGFR2. | ||
| M1934 | Tacrolimus (FK506) | Autophagy |
| Fujimycin; FR900506; Prograf | ||
| Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M1988 | Dabrafenib | Raf |
| GSK2118436 | ||
| Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. | ||
| M2045 | CEP-32496 | Raf |
| RXDX-105; Agerafenib | ||
| CEP-32496 is a potent orally active BRAF inhibitor with IC50 of 14 nM. | ||
| M2090 | MLN2480 | Raf |
| BIIB-024; Tovorafenib | ||
| MLN2480 is an orally active, CNS-permeable, highly selective inhibitor of type II RAF kinase that inhibits both monomeric (class I mutant) and dimeric forms of RAF and does not cause aberrant activation of the MAPK pathway caused by type I RAF inhibitors. In addition, MLN2480 inhibits the growth of tumors harboring BRAF fusions or BRAF V600 mutations and can be used in studies related to gliomas. | ||
| M2813 | LGX818 | Raf |
| Encorafenib | ||
| LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M5005 | Regorafenib Monohydrate | VEGFR/PDGFR |
| BAY 73-4506 monohydrate | ||
| Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. | ||
| M5059 | Furafylline | Cytochrome P450 (e.g. CYP17) |
| Furafylline was a potent, non-competitive inhibitor of high affinity phenacetin O-deethylase activity of microsomal fractions of human liver, a reaction catalysed by P450IA2, with an IC50 value of 0.07 microM. | ||
| M5925 | Regorafenib HCl | VEGFR/PDGFR |
| BAY73-4506 hydrochloride | ||
| Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. | ||
| M5950 | Sarafloxacin HCl | Antibiotic |
| A-56620 HCl | ||
| Sarafloxacin HCl is a hydrochloride salt form of sarafloxacin which is a quinolone antibiotic drug with IC50 of 0.96 μg/L. | ||
| M8459 | CD40-TRAF6 signaling inhibitor | Others |
| CD40-TRAF6 signaling inhibitor is a small molecule that binds to TRAF6, blocking interactions with CD40. | ||
| M8885 | Rafoxanide | Anti-infection |
| Rafoxanide is a novel allosteric inhibitor of SPAK and OSR1. | ||
| M8886 | RAF709 | Raf |
| RAF709 is a novel Raf kinase inhibitor with IC50 values of 0.4 and 1.5 nM for c-Raf and b-Raf, respectively. | ||
| M8897 | B-Raf-IN-1 | Raf |
| MDK36057 | ||
| B-Raf-IN-1 (MDK36057) is a potent b-Raf inhibitor with IC50 of 24 nM. | ||
| M9492 | B-Raf inhibitor 1 | Raf |
| ABM-0403 | ||
| B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively. | ||
| M9792 | Sarafotoxin S6c | Endothelin Receptor |
| Sarafotoxin S6c is a highly selective ETB endothelin receptor agonist (Ki values are 0.29 and 28000 nM at ETB and ETA receptors respectively). | ||
| M9913 | Mineral oil | Adjuvants |
| paraffin oil; Waste mineral oil | ||
| Mineral oil is an emollient cleanser and demulsifier of dirt trapped in pores, used as adjuvant. | ||
| M10152 | Naporafenib | Raf |
| LXH254 | ||
| Naporafenib (also known as LXH254) is an orally available inhibitor of C-Raf and B-Raf with potential antineoplastic activity. | ||
| M10373 | CB-103 | Notch |
| CB103; Limantrafin | ||
| CB-103 is a first-in-class, orally active inhibitor of the Notch transcription activation complex. CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis. | ||
| M10475 | Lifirafenib (BGB-283) | Raf |
| Beigene-283 | ||
| Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. | ||
| M10484 | Nalfurafine hydrochloride | Opioid Receptor |
| TRK-820 hydrochloride | ||
| Nalfurafine hydrochloride (TRK-820 hydrochloride) is a potent selective and orally active kappa opioid receptor (KOR) agonist. | ||
| M13929 | Vercirnon | CCR |
| GSK-1605786; CCX282-B; Traficet-EN | ||
| Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. | ||
| M13930 | Vercirnon sodium | CCR |
| GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium | ||
| Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. | ||
| M16672 | Sophoraflavanone G | Apoptosis |
| Kushenol F | ||
| Sophoraflavanone G induces MDA-MB-231 and HL-60 cells apoptosis through suppression of MAPK-related pathways. Sophoraflavanone G (Kushenol F) shows anti-tumor and anti-inflammatory properties. | ||
| M16740 | Putraflavone | Flavonoids |
| Putraflavone | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
